Juno Therapeutics, Inc. (NASDAQ:JUNO) EVP Robert Azelby sold 6,666 shares of the stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $54.95, for a total transaction of $366,296.70. Following the completion of the sale, the executive vice president now directly owns 79,998 shares in the company, valued at $4,395,890.10. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Robert Azelby also recently made the following trade(s):
- On Wednesday, September 13th, Robert Azelby sold 12,850 shares of Juno Therapeutics stock. The stock was sold at an average price of $44.95, for a total transaction of $577,607.50.
- On Tuesday, August 29th, Robert Azelby sold 12,869 shares of Juno Therapeutics stock. The stock was sold at an average price of $39.95, for a total transaction of $514,116.55.
Juno Therapeutics, Inc. (NASDAQ JUNO) opened at $58.48 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.08 and a current ratio of 4.77. Juno Therapeutics, Inc. has a one year low of $17.52 and a one year high of $61.59.
Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The firm had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million. During the same period last year, the firm earned ($0.57) earnings per share. The company’s quarterly revenue was up 115.4% on a year-over-year basis. equities analysts forecast that Juno Therapeutics, Inc. will post -3.62 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/11/05/robert-azelby-sells-6666-shares-of-juno-therapeutics-inc-juno-stock.html.
A number of equities analysts have recently commented on the stock. Wedbush raised shares of Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 target price on the stock in a research report on Tuesday, August 29th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $54.00 target price (up from $35.00) on shares of Juno Therapeutics in a research report on Tuesday, September 5th. Raymond James Financial, Inc. raised their target price on shares of Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a research report on Friday. Standpoint Research reaffirmed a “reduce” rating on shares of Juno Therapeutics in a research report on Thursday, August 31st. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $44.00 target price on shares of Juno Therapeutics in a research report on Friday, October 6th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $44.20.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jennison Associates LLC boosted its stake in shares of Juno Therapeutics by 162.0% during the third quarter. Jennison Associates LLC now owns 1,988,708 shares of the biopharmaceutical company’s stock valued at $89,213,000 after purchasing an additional 1,229,622 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in Juno Therapeutics in the third quarter valued at approximately $5,428,000. Swiss National Bank boosted its stake in Juno Therapeutics by 28.0% in the third quarter. Swiss National Bank now owns 133,500 shares of the biopharmaceutical company’s stock valued at $5,989,000 after acquiring an additional 29,200 shares in the last quarter. Asymmetry Capital Management L.P. acquired a new stake in Juno Therapeutics in the third quarter valued at approximately $1,380,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in Juno Therapeutics in the third quarter valued at approximately $510,000. Hedge funds and other institutional investors own 67.18% of the company’s stock.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
What are top analysts saying about Juno Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Juno Therapeutics Inc. and related companies.